<DOC>
	<DOCNO>NCT00459667</DOCNO>
	<brief_summary>The BEYOND Follow-Up study give patient participate precede BEYOND study opportunity continue treatment 500µg dose interferon beta ( IFNB ) 1b investigate safety tolerability profile interferon beta 1b 500µg longer-term treatment .</brief_summary>
	<brief_title>BEYOND Follow-up : Betaferon®/Betaseron® Efficacy Yielding Outcomes New Dose</brief_title>
	<detailed_description>Phase A ( 3 arm parallel group ) : All patient randomize BEYOND study ( Bayer 306440 ) either IFNB 1b group ( 250µg 500µg ) continue previously assign study medication , apply level blind BEYOND study , All patient randomize BEYOND study Copaxone patient premature discontinuation study medication BEYOND study receive open-label IFNB 1b 250µg . Phase B ( single arm ) : All patient receive open-label IFNB 1b 500µg ) Randomization : No randomization trial , patient 's allocation follow-up study depend prior trial group . The precede study randomize . The trial sponsor Bayer Schering Pharma AG , Germany , Bayer HealthCare Bayer HealthCare Pharmaceuticals Inc . Secondary outcome measure `` Assessment patient-reported outcome ( FAMS EQ 5D : The variable FAMS EQ-5D analyze due termination study start Phase B .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Completion BEYOND study 306440 schedule Relapsing multiple sclerosis Medical assessment investigator objection patient 's participation trial consider medical experience study 306440 . Special attention give laboratory abnormality clinically relevant liver , renal bonemarrow dysfunction . Females childbearing potential : Agreement practice adequate contraception method Negative pregnancy test No lactation Written inform consent Serious acute heart diseases History severe depression suicide attempt Epilepsy adequately control treatment Known allergy IFNs , human albumin mannitol Medical , psychiatric condition compromise patient 's ability understand patient information , give informed consent , comply trial protocol , complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Relapsing multiple sclerosis</keyword>
	<keyword>interferon beta 1b</keyword>
	<keyword>Betaferon</keyword>
	<keyword>Betaseron</keyword>
</DOC>